Kseniia Sergeevna Radaeva

Kseniia Sergeevna Radaeva

Auto-generated profile, based on publicly available information

Kseniia Sergeevna Radaeva

First St. Petersburg State Medical University named after I. P. Pavlov

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2024 in Traumatology and Orthopedics of Russia
Verified
Journal Article
Open access
PDF file
AKAlina Rashidovna Kasimova
Alina Rashidovna Kasimova
OTOlga Sergeevna Tufanova
Olga Sergeevna Tufanova
EGEkaterina Gordina
Ekaterina Gordina
AGAnton Nikolaevich Gvozdetsky
Anton Nikolaevich Gvozdetsky
KRKseniia Sergeevna Radaeva
Kseniia Sergeevna Radaeva
RTRashid Murtuzalievich Tikhilov
Rashid Murtuzalievich Tikhilov
Background. The number of surgeries on the musculoskeletal system is increasing every year. Along with the increasing access to orthopedic care, the number of patients with orthopedic infection, the etiological agents of which can be from various taxonomic groups, is also increasing. Staphylococcus aureus and different types of coagulase-negative staphylococci (CoNS), including S. epidermidis and S. lugdunensis, together are the causative agents in 70% of cases. Aim of the study — to analyze the dynamics of the microbial spectrum isolated from patients of the septic surgery department for the period from 2011 to 2022. Methods. We performed a retrospective analysis of the microbial spectrum isolated from patients who were treated in the septic surgery department from January 1, 2011 to December 31, 2022. The leading pathogens were microorganisms whose share in the spectrum exceeded 3.5%. Of the isolated pathogens, 48.8% were the only etiological agents, and microbial associations were detected in 51.2% of the isolated pathogens. Results. A total of 10,327 bacteria strains were identified over the 12-year period. The leading microorganisms causing orthopedic infection were Staphylococcus spp., Enterococcus spp., Propionibacterium spp., Pseudomonas aeruginosa, Corynebacterium spp., Streptococcus spp., Klebsiella spp. and Acinetobacter spp. In the dynamics of isolated pathogens during the analyzed period, several trends were determined: a decrease in the shares of S. aureus, Enterococcus spp., P. aeruginosa, Acinetobacter spp. and an increase in the shares of CoNS and Corynebacterium spp. Conclusion. During 12 years, in the microbial spectrum of orthopedic infection in patients of the septic surgery department of our Center, Gram-positive bacteria, in the majority representatives of the genus Staphylococcus, prevailed. At the same time, a significant decrease in the share of S. aureus strains and an increase in the frequency of isolation of various species of CoNS were registered. A significant decrease in the number of non-fermenting Gram-negative bacteria was also revealed.

1 November 2024 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
SNS. M. Noskov
S. M. Noskov
ААА. Н. Арефьева
А. Н. Арефьева
VBV. V. Banko
V. V. Banko
КRК. S. Radaeva
К. S. Radaeva
MGM. L. Gefen
M. L. Gefen
ISIgor Shohin
Igor Shohin
Introduction. Obesity is a growing public health issue in Russia, increasing the risk of cardiovascular diseases, type 2 diabetes, and hypertension. Controlling obesity involves lifestyle changes and pharmacotherapy. Semaglutide, an effective obesity treatment, stimulates insulin production and reduces appetite. Developing a generic semaglutide preparation will improve its availability in Russia.Aim. To study the comparative pharmacokinetics, bioequivalence, safety and tolerability of semaglutide products GP40331 and Wegovy using concentrations of 0.68 and 3.2 mg/ml in healthy volunteers under fasting conditions.Materials and methods. Bioequivalence studies, conducted per Good Clinical Practice, were open-label, randomized, and involved healthy male volunteers. Subjects received semaglutide at single doses of 0.25 mg (0.68 mg/ml) and 0.5 mg (3.2 mg/ml) under fasting. Bioequivalence was determined by the 90% CI of the ratios of geometric mean values of the primary pharmacokinetic parameters (AUC0-t, Cmax). Semaglutide concentrations were measured using high-performance liquid chromatography with tandem mass spectrometry.Results. The 90% CI values for the ratios of geometric means of the primary PK parameters of semaglutide were 90.22–110.29 and 86.48–108.98% (0.68 mg/ml) and 90.62–115.71 and 92.86–113.51% (3.2 mg/ml). Comparable safety was proven for both concentrations.Conclusion. GP40331 and Wegovy at 0.68 and 3.2 mg/mL are bioequivalent and equally safe.

25 August 2023 in Current Pediatrics
Verified
Journal Article
Open access
PDF file
AKAlexey S. Kolbin
Alexey S. Kolbin
KRKseniya S. Radaeva
Kseniya S. Radaeva
Drug dosing remains one of the topical issues of modern pediatrics. Insufficient number of clinical studies, vulnerable patient populations (preterm newborns, patients with renal and/or hepatic insufficiency, obesity), and high risk of polypragmasy create additional difficulties for practicing physicians. This review provides description of currently used approaches to drugs dosing in children. It has been shown that prognostic models should be used for solving drugs dosing issues regarding characteristics of young patients. Such models include: physiologically based pharmacokinetic modelling; population pharmacokinetic analysis; model-based precision dosing; modeling and simulation approach; use of real world data; and pharmacogenetic testing-based dosing. These models use information from preclinical and clinical stu

2 July 2024 in Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice
Verified
Journal Article
Open access
PDF file
AKA. S. Kolbin
A. S. Kolbin
KRK. S. Radaeva
K. S. Radaeva
AMA. S. Motrinchuk
A. S. Motrinchuk
ISI. R. Svechkareva
I. R. Svechkareva
Relevance. Clinical pharmacology is a rapidly evolving field of medicine. The advent of modern technologies has led. The continued evolution of clinical pharmacology, as reflected in publications in specialized medical journals.The aim of this study was to determine how new trends in clinical pharmacology were reflected in the publications of the leading clinical pharmacology journals in Russia during the period from 2015-2021, to conduct a comparative analysis of trends with international journals from 2015-2021.Materials and methods. Original articles published in leading Russian journals were analyzed and categorized into relevant key areas of interest, drug modalities, and therapeutic areas based on the content of the publications independently by three authors. Publications in which authors expressed divergent opinions were discussed until consensus was reached using a modified Delphi method. A comparative analysis was then performed with the results of a similar analysis published in journal “Clinical Pharmacology and Therapeutics”.Results. Most Russian journals and publications have focused on real-world data. The topics most frequently covered in international journals were pharmacometrics, machine learning, and pharmacogenetics. In third place were real-world data. The leading therapeutic areas represented in publications in both Russian and international journals were cardiology, oncology, and infectious diseases. Most publications have focused on various aspects of small molecule use.Conclusions. The novel trends in clinical pharmacology are reflected in the scientific articles published in specialized journals. The principal trends observed in Russian publications are consistent with international tendencies.

24 January 2023 in Real-World Data & Evidence
Verified
Journal Article
Open access
PDF file
KRK. S. Radaeva
K. S. Radaeva
EVE. V. Verbitskaya
E. V. Verbitskaya
The growing volume and complexity of data that is currently being collected in a variety of settings and devices is of varying degrees and quality, posing a challenge for the public health sector to develop a robust electronic system that can be collected, analyzed and made available to clinicians. The creation of a system, the development of the capabilities and potential of information technologies for obtaining, managing and analyzing a large amount of data, will allow to identify facts regarding the safety and effectiveness of the use of drugs, to investigate the validity of statements made by pharmaceutical companies, to obtain a more accurate characterization of treatment methods in individual healthcare sectors and to provide doctors with quick and constant access to this information, which will facilitate its use in the treatment of patients. The development of such a tool is a priority for the health care system in a changing world. An example of such a tool is the Data Analysis and Real Word Interrogation Network (DARWIN EU®), which was launched on February 9, 2022 by the European Medicines Agency. The purpose of this article is to review the history of creation, organizational structure, operating principles, current experience of the European Union regulatory network and comparison with the experience of international regulatory bodies. The article, along with the experience of the European Medicines Agency, also considers similar initiatives in the US and Canada.

14 October 2023 in Real-World Data & Evidence
Verified
Journal Article
Open access
PDF file
KRKsenia S. Radaeva
Ksenia S. Radaeva
MPM. V. Pchelintsev
M. V. Pchelintsev
In 2021, the U.S. Food and Drug Administration (FDA) issued draft guidance on the use of electronic health records and medical claims data for regulatory decisions. The draft guidance provides recommendations for sponsors regarding the use of real-world data in conducting studies. It also addresses the challenges and limitations associated with the use of these data and provides recommendations to overcome them. The purpose of this article is to provide a brief overview of key aspects of the FDA's guidance on the use of electronic health record data in regulatory decision making.